| Literature DB >> 35007440 |
Natalie Pitch1,2, Stephanie Stefaniuk2, Meghan MacMillan2,3, Jennifer Catsburg2, Abha A Gupta2,4, Tushar Vora2,4.
Abstract
Background: The Princess Margaret Cancer Centre (PM) established the adolescent and young adult (AYA) oncology program in 2014 to address the unique needs of AYA by delivering targeted, evidence-based care through a multidisciplinary team.Entities:
Keywords: AYA concerns; adolescent and young adult; program analysis; survivorship
Mesh:
Year: 2022 PMID: 35007440 PMCID: PMC9057888 DOI: 10.1089/jayao.2021.0156
Source DB: PubMed Journal: J Adolesc Young Adult Oncol ISSN: 2156-5333 Impact factor: 1.757
Modified Edmonton Symptom Assessment Screening Scale—Princess Margaret Cancer Centre, Adolescent and Young Adult Program
| AYA screening tool | ||||||||||||
| Please circle the number that best describes you: | ||||||||||||
| No concern with work/school | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Significant work/school concerns |
| No concern with finances | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Significant financial concerns |
| Not anxious about my future | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Very anxious about my future |
| I have excellent social supports | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | I do not have individuals in my life that are supporting me |
| No concern about my appearance | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Significant concern about my appearance |
| No concerns about my sexual health | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Significant concerns about my sexual health |
| No concerns about my fertility | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Significant concerns about my fertility |
| No difficulty understanding info about my cancer | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Significant difficulty understanding info about my cancer |
| No concerns with diet/nutrition | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Significant concern with diet/nutrition |
| No difficulty navigating the hospital system | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Significant difficulty navigating the hospital system |
| No concerns with physical activity/exercise | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Significant concerns with physical activity/exercise |
Distribution of Adolescent and Young Adult Across Age at Assessment, Diagnoses, and Time since Diagnosis
| Age at assessment (years), | |
| 18–24 | 355 (31.5) |
| 25–34 | 540 (47.9) |
| 35–39 | 233 (20.6) |
| Diagnoses, | |
| Lymphoma | 251 (22.2) |
| Leukemia | 207 (18.4) |
| Breast | 162 (14.4) |
| GU | 102 (9.0) |
| Sarcoma | 84 (7.4) |
| Gynecological | 64 (5.7) |
| CNS | 60 (5.3) |
| GI | 52 (4.6) |
| H&N | 36 (3.2) |
| Benign | 29 (2.6) |
| BMT | 24 (2.1) |
| Others | 57 (5.1) |
| Time since diagnosis (days), | |
| 0–30 | 305 (32.3) |
| 31–90 | 242 (25.7) |
| 91–365 | 167 (17.7) |
| >365 | 229 (24.3) |
BMT, bone marrow transplant; CNS, central nervous system; GI, gastrointestinal; GU, genitourinary; H&N, head and neck.
Reported Concerns Across Age at Assessment, Diagnoses and Time Since Diagnosis
| Fertility | Sexual health | Coping | Body image | Exercise | Diet | Financial | Work/school | Social | |
|---|---|---|---|---|---|---|---|---|---|
| Total | |||||||||
| | 882 (78.2) | 224 (19.9) | 283 (25.0) | 164 (14.5) | 267 (23.7) | 221 (19.6) | 92 (8.2) | 472 (41.8) | 61 (5.4) |
| Age at assessment (years) | |||||||||
| 18–24 (355, 31.5) | 266 (74.9) | 74 (20.8) | 78 (22.0) | 51 (14.4) | 79 (22.3) | 54 (15.2) | 35 (9.9) | 191 (53.8) | 17 (4.8) |
| 25–34 (540, 47.9) | 443 (82.0) | 104 (19.3) | 144 (26.7) | 78 (14.4) | 127 (23.5) | 112 (20.7) | 47 (8.7) | 201 (37.2) | 30 (5.6) |
| 35–39 (233, 20.7) | 173 (74.2) | 46 (19.7) | 61 (26.2) | 35 (15.0) | 61 (26.2) | 55 (23.6) | 10 (4.3) | 80 (34.3) | 14 (6.0) |
| 0.011 | 0.843 | 0.259 | 0.972 | 0.545 | 0.044 | 0.044 | <0.001 | 0.797 | |
| Diagnoses | |||||||||
| Lymphoma (251, 22.2) | 210 (83.7) | 53 (21.1) | 71 (28.3) | 41 (16.3) | 56 (22.3) | 47 (18.7) | 20 (8.0) | 116 (46.2) | 13 (5.2) |
| Leukemia (207, 18.4) | 185 (89.4) | 48 (23.2) | 38 (18.4) | 27 (13.0) | 52 (25.1) | 29 (14.0) | 25 (12.1) | 94 (45.4) | 5 (2.4) |
| Breast (162, 14.4) | 143 (88.3) | 44 (27.2) | 44 (27.2) | 51 (31.5) | 48 (29.6) | 50 (30.9) | 15 (9.3) | 75 (46.3) | 17 (10.5) |
| GU (102, 9.0) | 82 (80.4) | 9 (8.8) | 15 (14.7) | 8 (7.8) | 19 (18.6) | 18 (17.6) | 5 (4.9) | 31 (30.4) | 3 (2.9)[ |
| Sarcoma (84, 7.4) | 45 (53.6) | 14 (16.7) | 25 (29.8) | 9 (10.7) | 27 (32.1) | 15 (17.9) | 6 (7.1) | 43 (51.2) | 3 (3.6)[ |
| Gynecological (64, 5.7) | 37 (57.8) | 21 (32.8) | 28 (43.8) | 7 (10.9) | 22 (34.4) | 18 (28.1) | 2 (3.1)[ | 30 (46.9) | 5 (7.8)[ |
| CNS (60, 5.3) | 40 (66.7) | 9 (15.0) | 21 (35.0) | 4 (6.7)[ | 12 (20.0) | 15 (25.0) | 2 (3.3)[ | 23 (38.3) | 1 (1.7)[ |
| GI (52, 4.6) | 37 (71.2) | 6 (11.5) | 8 (15.4) | 2 (3.8)[ | 8 (15.4) | 4 (7.7)[ | 4 (7.7)[ | 14 (26.9) | 4 (7.7)[ |
| H&N (36, 3.2) | 26 (72.2) | 8 (22.2) | 9 (25.0) | 5 (13.9) | 10 (27.8) | 9 (25.0) | 5 (13.9) | 14 (38.9) | 4 (11.1)[ |
| Benign (29, 2.6) | 21 (72.4) | 2 (6.9)[ | 3 (10.3)[ | 2 (6.9)[ | 2 (6.9)[ | 4 (13.8)[ | 4 (13.8)[ | 8 (27.6) | 0[ |
| BMT (24, 2.1) | 21 (87.5) | 5 (20.8) | 7 (29.2) | 4 (16.7)[ | 1 (4.2)[ | 1 (4.2)[ | 0[ | 9 (37.5) | 1 (4.2)[ |
| Others (57, 5.1) | 35 (61.4) | 5 (8.8) | 14 (24.6) | 4 (7.0)[ | 10 (17.5) | 11 (19.3) | 4 (7.0)[ | 15 (26.3) | 5 (8.8) |
| <0.001 | <0.001 | <0.001 | <0.001 | 0.006 | <0.001 | 0.175 | 0.005 | 0.026 | |
| Time since diagnosis (days) | |||||||||
| 0–30 (305, 32.3) | 283 (92.8) | 61 (20.0) | 64 (21.0) | 46 (15.1) | 70 (23.0) | 62 (20.3) | 20 (6.6) | 119 (39.0) | 22 (7.2) |
| 31–90 (242, 25.7) | 209 (86.4) | 52 (21.5) | 71 (29.3) | 43 (17.8) | 82 (33.9) | 67 (27.7) | 22 (9.1) | 116 (47.9) | 10 (4.1) |
| 91–365 (167, 17.7) | 122 (73.0) | 37 (22.2) | 42 (25.1) | 36 (21.6) | 45 (26.9) | 35 (21.0) | 17 (10.2) | 72 (43.1) | 2 (1.2) |
| >365 (229, 24.3) | 144 (62.9) | 46 (20.1) | 66 (28.8) | 21 (9.2) | 50 (21.8) | 33 (14.4) | 16 (7.0) | 114 (49.8) | 4 (1.7) |
| <0.001 | 0.931 | 0.093 | 0.005 | 0.010 | 0.028 | 0.447 | 0.056 | 0.002 |
Not applicable—Expected cell size as per analysis ≥5, hence not applicable.
BMT, bone marrow transplant; CNS, central nervous system; GI, gastrointestinal; GU, genitourinary; H&N, head and neck.